Vera reported $556.8 million in cash, cash equivalents, and marketable securities as of June 30, 2025, which combined with its undrawn debt facility, Vera believes to be sufficient to fund operations through potential approval and U.S. commercial launch of atacicept and beyond.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VERA:
- Tesla grants Musk big payout, Wayfair reports Q2 beat: Morning Buzz
- Coinbase downgraded, Spotify upgraded: Wall Street’s top analyst calls
- Vera Therapeutics downgraded to Peer Perform from Outperform at Wolfe Research
- Millions in Insider Buying Point to These 2 Stocks — Here’s What It Could Signal
- Vera Therapeutics Inc put volume heavy and directionally bearish